|
|
Volumn 9, Issue 2, 2008, Pages 78-84
|
|
Advances in genomic and proteomic studies of non-small-cell lung cancer: Clinical and translational research perspective
|
|
Author keywords
Biomarkers; Predictive markers; Prognostic markers; Tyrosine kinase inhibitors
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
BIOLOGICAL MARKER;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
CYCLIN DEPENDENT KINASE INHIBITOR 1B;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;
GEFITINIB;
GEMCITABINE;
NAVELBINE;
PACLITAXEL;
PLACEBO;
PLATINUM;
PROTEIN P53;
PROTEIN RRM1;
PROTEIN TYROSINE KINASE INHIBITOR;
TAXANE DERIVATIVE;
ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER CLASSIFICATION;
CANCER DIAGNOSIS;
CANCER GROWTH;
CANCER RISK;
CANCER STAGING;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL STUDY;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
GENE MUTATION;
GENETIC ANALYSIS;
HUMAN;
LABORATORY TEST;
LUNG NON SMALL CELL CANCER;
MEDICAL INFORMATION;
MEDICAL RESEARCH;
MONOTHERAPY;
PROTEIN ANALYSIS;
PROTEIN EXPRESSION;
RNA TRANSLATION;
SENSITIVITY AND SPECIFICITY;
SHORT SURVEY;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
|
|
EID: 43049096087
PISSN: 15257304
EISSN: None
Source Type: Journal
DOI: 10.3816/CLC.2008.n.012 Document Type: Review |
|
Times cited : (20)
|
|
References (68)
|
